This week, US and Liberian authorities started a clinical trial to assess the security and adequacy of exploratory Ebola medication ZMapp as indicated by the US National Institute of Allergy and Infectious Disease (NIAID). ZMapp is a product of California-based Mapp Biopharmaceuticals Inc.
The medication is made out of three separate proteins named monoclonal antibodies that supposed to contain the spread of the infection inside the body.
Dr. Anthony Fauci, executive of the National Institute of Allergy and Infectious Diseases declared:
“Although ZMapp has been used to treat several Ebola-infected patients in recent months, we cannot determine if the drug actually benefited those patients because it was not administered within the context of a clinical trial.”
Accordingly, this clinical trial would help the doctors establish whether ZMapp and different treatments are safe and suitable for utilization in the current obliterating episode in West Africa and in future viral outbreaks.
The U.S. institute also mentioned that study specialists believe that there is a need for adaptability in the way the trial is conducted in order to address the changing way of the Ebola outbreak in West Africa. They further noted that different sites in the region will also be considered for the trial if interest is voiced in that direction. The trial is scheduled to end on Dec 2016.
Since the Ebola episode there have been more than 9,400 casualties in Liberia, Guinea and Sierra Leone. The infection causes hemorrhagic fever in people and right now it has no cure, treatment or immunization.
The study is a randomized contained trial involving both adults and children who were admitted to Ebola treatment facilities in Liberia, together with individuals who may have been infected with Ebola through secondary transmission in the United States. Health-care personnel infected with the virus who came back to the U.S. for treatment will likewise be qualified.
The individuals who effectively enlist in the trial will get a standard treatment for Ebola, which incorporates intravenous liquids, containing the virus and keeping up oxygen levels and circulatory strain.
A control group will only get this treatment while a second group of subjects gets three different intravenous mixtures of ZMapp administered one every three days.
Dr. Kevin Whaley, CEO of Mapp Biopharmaceutical noted in an announcement that the company has been working to develop an Ebola treatment for more than 10 years. As such, they are now enthusiastic about the backing and responsiveness of the governments and orgs devoted to finding a suitable treatment for the obliterating illness.
Image Source: RB Magazine